The University of Hong Kong

Main Content

   Grant(s) - only listing with the capacity of Pricincipal Investigator

1. Principal Investigator: A double-blind, randomised, placebo-controlled trial of berberine as an adjuvant to treat antipsychotic-induced metabolic syndrome in patients with schizophrenia spectrum disorders. Health and Medical Research Fund (HMRF) (project reference no.: 14151891), HK$1,188,844, August 1, 2017 – July 31, 2019.
2. Principal Investigator: the anxiolytic and antidepressant effects of Shexiang Baoxin Pill (SBP) on the anxiety- and depression-like animal model. Contracted research project with Shanghai Hutchison Pharmaceuticals. HK$264,706, August 1, 2016 – July 31, 2017.
3. Principal Investigator: Herbal compounds protect against antipsychotic-induced weight gain and metabolic syndrome in rats. Seed Funding Programme for Basic Research (project reference no.: 201511159088), HK$45,980, April 1, 2016 – March 31, 2018.
4. Principal Investigator: A preliminary evaluation of the efficacy and safety of acupoint-based cranial electromechanical stimulation (ACEMS) in patients with insomnia. Seed Funding Programme for Applied Research (project reference no.: 201511160003). HK$100,000, March 1, 2016 – February 28, 2017.
5. Principal Investigator: Serotonin type 3 (5HT3) receptor antagonists protect against traumatic brain injury. Seed Funding Program for Basic Research (project reference no.: 201411159081), HK$56,625, June 1, 2015 – May 31, 2017.
6. Principal Investigator: Development of acupuncture on post-stroke depression. HK Hospital Authority fund (HKU project reference no.: 20006344). HK$495,420. October 1, 2015 - September 30, 2017.
7. Principal Investigator: A double-blind, randomized controlled trial of A Drop Water™ essential oil in patients with chronic prostatitis (HKU project reference no.: 200007345). Donation from Hong Kong Golden Eagle Enterprise Group Limited, HK$340,000. November 2014.
8. Principal Investigator: An assessor-blinded, randomised controlled trial of acupuncture to prevent chemobrain in breast cancer patients, Health and Medical Research Fund (HMRF) (project reference no.: 12133711), HK$989,030, August 1, 2015 – July 31, 2017.
9. Principal Investigator: A novel therapeutic equipment called Acupoint-based Cranial Electromechanical Stimulator (ACEMS) for stress-associated symptoms. Seed Funding Programme for Applied Research (project reference no.: 201309160020). HK$100,000, July 1, 2014 – June 30, 2015.
10. Principal Investigator: Acupuncture prevents chemobrain in patients with breast cancer: is it associated with the protection against cytokine production, epigenetic modification and microstructural changes of the brain? Seed Funding Program for Basic Research (project reference no.: 201311159070), HK$83,800, April 1, 2014 - March 31, 2016.
11. Principal Investigator: The identification of psychopharmacological mechanisms of glycyrrhetinic acid in reducing antipsychotic-induce hyperprolactinemia. General Research Fund (GRF) of Research Grant Council of HKSAR (project reference no.: 785813): HK$519,619, 2014-2016.
12. Principal Investigator: The identification of psychopharmacological mechanisms of glycyrrhetinic acid in reducing antipsychotic-induced hyperprolactinemia. Seed Funding Program for Basic Research (project reference no.: 201210159051), HK$84,100, 2013-2014.
13. Principal Investigator: Does concomitant use with Chinese medicines alter pharmacokinetic and toxicological profiles of antipsychotic drugs in experimental rats? Implication for herb-drug interactions. Health and Health Service Research Fund (HMRF) (project reference no.: 10111381): HK$911,816, 2013-2015.
14. Principal Investigator: The identification of central neural network for antidepressant effects of dense cranial electroacupuncture stimulation - a positron emission topographic (PET) study. General Research Fund (GRF) of Research Gant Council of HKSAR (project reference no.: 786611): HK$900,000, 2012-2015.
15. Principal Investigator: The herbal medicine Peony-Glycyrrhiza Decoction (PGD) as an adjunctive therapy to treat antipsychotic-induced hyperprolactinemia in female patients with schizophrenia: a double-blind, randomized, placebocontrolled study. Health and Health Service Research Fund (HHSRF) (project reference no.: 09101141): HK$999,332, 2012-2014.
16. Principal Investigator: A single-blind, randomised, sham controlled study of electroacupuncture in accelerating the onset of antidepressant action of selective serotonin reuptake inhibitors via serotonergic mechanisms. Health and Health Service Research Fund (HHSRF) (project reference no.: 06070831), HK$762,496, 2008-2011.
17. Principal Investigator: A single-blind, randomized, controlled trial of electroacupuncture combined with antidepressants in treating patients with post-stroke depression. HK Hospital Authority fund (HKU project reference no.: 21006031). HK$499,100. (2010-2012).
18. Principal Investigator: To evaluate the efficacy and effectiveness of CHM on symptoms caused by benign prostate hyperplasia and early prostate cancer - systematic review. HK Hospital Authority fund (HKU project reference no.: 20006343). HK$300,000. (2011-2012).
19. Principal Investigator: Provision of systematic review on the Efficacy and Effectiveness of CHM on Chronic Obstructive Pulmonary Disease (COPD). HK Hospital Authority fund (HKU project reference no.: 20006344). HK$300,000. (2011-2012).
20. Principal Investigator: Additional management of dysthymia and depressive Episodes. HK Hospital Authority fund. HK$300,000. (2008-2009).
21. Principal Investigator: A 12-week, open-labeled, pilot study of ligustilide in 30 patients with postpartum major depressive disorder. Kadoorie Charitable Foundation (HKU project reference no.: 21005180). HK$150,000 (2007-2009).
22. Principal Investigator: Multiple pharmacological mechanisms associated with effects of Peony-Glycyrrhiza Decoction (PGD), an herbal preparation, in suppressing hyperprolactinemia. HKU Seed Funding Program for Basic Research (project reference no.: 201011159095): HK$58,000, 2011-2013.
23. Principal Investigator: A novel herbal preparation to treat antipsychotic-induced hyperprolactinemia in patients with schizophrenia: a randomized controlled study. Seed Funding Program for Applied Research (project reference no.: 201102160005). HK$100,000, 2011-2012.
24. Principal Investigator: Central mechanisms involved in dense cranial electroacupuncture stimulation in treating major depression - a positron emission topographic (PET) study. Seed Funding Program for Basic Research (project reference no.: 200911159062), HK$61,000, 2009-2011.
25. Principal Investigator: An epidemiological study of the concomitant use of Chinese medicine and antipsychotic drugs in Hong Kong schizophrenic population: implication for potential herb-antipsychotic interactions. HKU Intramural Fund, HK$80,000. 2009-2010.
26. Principal Investigator: Pharmacokinetic and therapeutic characterization of liguslitide nasal spray for premenstrual syndromes. Seed Funding Program for Applied Research (project reference no.: 200802160012), HK$127,000, 2008-2009.
27. Principal Investigator: Behavioral and genomic/proteomic mechanisms of D1 agonistic-D2 antagonistic dual action of stepholidine against negative and cognitive symptoms of schizophrenia. HKU Seed Funding Program for Basic Research (project reference no.: 200611159027), HK$50,000, 2008-2009.
28. Principal Investigator: The development of a clinical-case search system to introduce case-study learning mode into Chinese medical curricula. Leung Kau Kui Research and Teaching Endowment Fund - Teaching Grants (project reference no.: 200801165004), HK$50,000, 2008-2009.
29. Principal Investigator: Therapeutic effects of ligustilide and mechanisms of its actions against premenstrual dysphoric disorder (PMDD). HKU Seed Funding Program for Basic Research (project reference no.: 200611159027), HK$120,000, 2007-2008.
30. Principal Investigator: The Establishment of Neurobehavioral Experiments into the Acupuncture Course (BCHM3003, 針灸學) of Undergraduate Chinese Medicine Programs. HKU Run Run Shaw Research and Teaching Endowment Fund (project reference no.: 200701166006), HK$40,000, 2007-2008.
31. Principal Investigator: A double-blind, randomized, placebo controlled trial of the herbal medicine Xiao-Yao-San monotherapy and adjunctive therapy with carbamazepine in the treatment of 520 patients with bipolar disorder. Principal Investigator. US$708,000, 9/2002 - 10/2005, the Stanley Medical Research Institute (SMRI), Bethesda, Maryland, USA.
32. Principal Investigator: A 12-week, double-blind, randomized, placebo-controlled trial of ondansetron (Zofran) as adjunctive therapy with haloperidol in 120 treatment-resistant patients with schizophrenia. Principal Investigator, US$213,900, 9/2004 - 10/2005, the Stanley Medical Research Institute (SMRI), Bethesda, Maryland, USA.
33. Principal Investigator: Inhibitory effects of the Chinese herb Xuduan (Dipsacus Asper) on beta-amyloid peptides in animal models of Alzheimer’s disease. RMB60,000. 01/95 - 12/97. National Natural Scientific Foundation of China, Beijing, China.
34. Principal Investigator: Hypothalamic aging. CNY5,000. 12/89 - 11/91. Outstanding Young Scientist Program of Shaanxi Province, Xi’an, Shaanxi, China.